Advanced Filters
noise

solid-tumors Clinical Trials

A listing of solid-tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,625 clinical trials

A Study of GQ1010 in Subjects With Advanced Solid Tumors

This is an open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of GQ1010 and preliminary anti-tumor efficacy in advanced malignant solid tumor subjects

18 years of age All Phase 1/2

Study of SC-102 in Patients With Advanced Solid Tumors

This study will evaluate the safety, PK profile, and anti-cancer efficacy of SC-102 in subjects with advanced solid tumors

18 - 75 years of age All Phase 1
j jian zhang, phD

A Study of SKB518 in Patients With Advanced Solid Tumors

This is a first-in-human (FIH), phase 1, multicenter, open-label, dose-escalation study of SKB518 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity in adult subjects with advanced or metastatic solid tumor relapsed/refractory to standard therapies or for which no effective standard therapy is available.

18 years of age All Phase 1
S Sheng Zhang, PhD

Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies

This study is a single-center, multi-cohort, phase II clinical trial. Eligible patients with HER2-positive advanced solid tumors were enrolled after providing informed consent. A total of 90 patients were allocated into three cohorts (30 patients each): those with Extramammary Paget's Disease (EMPD), rare solid tumors, or urothelial carcinoma, who had …

18 years of age All Phase 2
C Changsong Qi, MD

TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors

This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of TC-G203 in patients with GPC3-positive recurrent or metastatic solid tumors who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to …

18 - 75 years of age All Phase 0
C Caicun Zhou, PhD

A Study of HDM2024 in Participants With Advanced Solid Tumors

The goal of this clinical trial is to learn if the study drug can work in advanced cancer patients. The main questions it aims to answer are: Is the drug safe and tolerable ? Does the drug exhibit antitumor activity ? Participants will receive the study drug once every three …

18 - 75 years of age All Phase 1
S Site Contact

A Study of TAK-505 in Adults With Solid Tumors

Solid tumors occur when cells in an organ or tissue (for example in the lung or liver) start growing out of control (cancer) and form a lump or mass of cells. These solid cancers may grow very far in the general area where they started (called locally advanced) or may …

18 years of age All Phase 1/2
J Jihui Hao, MD

A Single-Arm, Open-Label, Phase I Study of GK01 for Advanced Solid Tumor

This study is a Phase I, open-label, single-arm clinical trial to evaluate the safety, pharmacokinetics, and preliminary efficacy of GK01 in patients with advanced solid tumors.

18 - 70 years of age All Phase 1
Z Zhen J Peng, Phd

Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors

This is a multicenter, open-label, Phase 1/2 master protocol evaluating autologous dual-target CAR-T cell therapy in adults with advanced solid cancers. After central biomarker screening, each participant is assigned the best-matched dual-target construct from a predefined target-pair library. The trial is designed to test whether biomarkerguided dual targeting can improve …

18 - 75 years of age All Phase 1/2
H Han wei dong, Ph.D

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

The goal of this first-in-human, single-center, prospective, open-label, phase 1/2 trial is to evaluate the safety and efficacy of the interferon alpha expressing mesenchymal stromal cells (MSC-IFNα) combined with or without immunochemotherapy in patients with locally advanced/metastatic solid tumors. The main questions aimed to answer are 1) to evaluate the …

18 - 75 years of age All Phase 1/2

Simplify language using AI